-
公开(公告)号：US20220152205A1
公开(公告)日：2022-05-19
申请号：US17667083
申请日：2022-02-08
发明人： Adrienne Boire , Joan Massague
IPC分类号： A61K45/00 , A61K31/7105 , A61P35/04 , A61K31/166 , A61K31/4745 , A61K31/7068 , G01N33/574
摘要： The present invention relates to methods and compositions for modulating the blood CSF barrier and for diagnosing, preventing and/or treating leptomeningeal metastasis. In particular embodiments of the invention, the permeability of the blood CSF barrier is modulated by agonists or antagonists of Complement Component 3 (C3) or its receptor.
-
公开(公告)号：US11305014B2
公开(公告)日：2022-04-19
申请号：US15984087
申请日：2018-05-18
发明人： Adrienne Boire , Joan Massague
IPC分类号： A61K45/00 , A61K31/7105 , A61P35/04 , A61K31/166 , A61K31/4745 , A61K31/7068 , A61K45/06 , G01N33/574
摘要： The present invention relates to methods and compositions for modulating the blood CSF barrier and for diagnosing, preventing and/or treating leptomeningeal metastasis. In particular embodiments of the invention, the permeability of the blood CSF barrier is modulated by agonists or antagonists of Complement Component 3 (C3) or its receptor.
-
公开(公告)号：US20220105069A1
公开(公告)日：2022-04-07
申请号：US17345572
申请日：2021-06-11
发明人： Joan Massague , Adrienne Boire , Qing Chen
IPC分类号： A61K31/352 , A61P35/04 , A61P35/00 , A61K45/06 , A61K31/196 , A61K31/555 , A61K31/7105 , A61K31/282 , G01N33/50
摘要： The present invention relates to methods for treating brain metastasis by inhibiting gap junction functionality. It is based, at least in part, on the discovery that cancer cells expressing Protocadherin 7 and Connexin 43 form gap junctions with astrocytes that promote the growth of brain metastases, and that inhibition of Protocadherin 7 and/or Connexin 43 expression in cancer cells reduce progression of brain metastases. It is further based on the discovery that treatment with gap junction inhibitors tonabersat and meclofenamate inhibited progression of brain metastatic lesions and enhanced the anti-cancer activity of the conventional chemotherapeutic agent, carboplatin.
-
公开(公告)号：US10413522B2
公开(公告)日：2019-09-17
申请号：US15462253
申请日：2017-03-17
发明人： Joan Massague , Adrienne Boire , Qing Chen
IPC分类号： A61K45/06 , A61P35/00 , A61P35/04 , G01N33/50 , A61K31/196 , A61K31/282 , A61K31/352 , A61K31/555 , A61K31/7105
摘要： The present invention relates to methods for treating brain metastasis by inhibiting gap junction functionality. It is based, at least in part, on the discovery that cancer cells expressing Protocadherin 7 and Connexin 43 form gap junctions with astrocytes that promote the growth of brain metastases, and that inhibition of Protocadherin 7 and/or Connexin 43 expression in cancer cells reduce progression of brain metastases. It is further based on the discovery that treatment with gap junction inhibitors tonabersat and meclofenamate inhibited progression of brain metastatic lesions and enhanced the anti-cancer activity of the conventional chemotherapeutic agent, carboplatin.
-
公开(公告)号：US20240050385A1
公开(公告)日：2024-02-15
申请号：US18155115
申请日：2023-01-17
申请人： MEMORIAL SLOAN-KETTERING CANCER CENTER , SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH , MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES
发明人： Adrienne Boire , Yudan Chi
CPC分类号： A61K31/16 , A61P35/04 , A61K9/0019 , A61K2121/00
摘要： The present disclosure relates to the use of iron chelation to prevent and/or treat leptomeningeal metastasis. In certain embodiments, the present disclosure provides methods for the prevention and/or treatment of leptomeningeal metastasis that include the administration of an iron chelator to a subject. The present disclosure further provides kits for performing such methods.
-
公开(公告)号：US11058665B2
公开(公告)日：2021-07-13
申请号：US16570180
申请日：2019-09-13
发明人： Joan Massague , Adrienne Boire , Qing Chen
IPC分类号： A61P35/04 , A61P35/00 , A61K45/06 , A61K31/196 , A61K31/555 , A61K31/282 , A61K31/352 , A61K31/7105 , G01N33/50
摘要： The present invention relates to methods for treating brain metastasis by inhibiting gap junction functionality. It is based, at least in part, on the discovery that cancer cells expressing Protocadherin 7 and Connexin 43 form gap junctions with astrocytes that promote the growth of brain metastases, and that inhibition of Protocadherin 7 and/or Connexin 43 expression in cancer cells reduce progression of brain metastases. It is further based on the discovery that treatment with gap junction inhibitors tonabersat and meclofenamate inhibited progression of brain metastatic lesions and enhanced the anti-cancer activity of the conventional chemotherapeutic agent, carboplatin.
-
公开(公告)号：US12029717B2
公开(公告)日：2024-07-09
申请号：US17345572
申请日：2021-06-11
发明人： Joan Massague , Adrienne Boire , Qing Chen
IPC分类号： A61K31/352 , A61K31/196 , A61K31/282 , A61K31/555 , A61K31/7105 , A61K45/06 , A61P35/00 , A61P35/04 , G01N33/50
CPC分类号： A61K31/352 , A61K31/196 , A61K31/282 , A61K31/555 , A61K31/7105 , A61K45/06 , A61P35/00 , A61P35/04 , G01N33/5011 , G01N2333/705 , A61K31/196 , A61K2300/00 , A61K31/352 , A61K2300/00 , A61K31/555 , A61K2300/00 , A61K31/7105 , A61K2300/00
摘要： The present invention relates to methods for treating brain metastasis by inhibiting gap junction functionality. It is based, at least in part, on the discovery that cancer cells expressing Protocadherin 7 and Connexin 43 form gap junctions with astrocytes that promote the growth of brain metastases, and that inhibition of Protocadherin 7 and/or Connexin 43 expression in cancer cells reduce progression of brain metastases. It is further based on the discovery that treatment with gap junction inhibitors tonabersat and meclofenamate inhibited progression of brain metastatic lesions and enhanced the anti-cancer activity of the conventional chemotherapeutic agent, carboplatin.
-
公开(公告)号：US20200085781A1
公开(公告)日：2020-03-19
申请号：US16570180
申请日：2019-09-13
发明人： Joan Massague , Adrienne Boire , Qing Chen
IPC分类号： A61K31/352 , A61P35/04 , A61P35/00 , A61K45/06 , A61K31/196 , A61K31/555 , A61K31/7105 , A61K31/282 , G01N33/50
摘要： The present invention relates to methods for treating brain metastasis by inhibiting gap junction functionality. It is based, at least in part, on the discovery that cancer cells expressing Protocadherin 7 and Connexin 43 form gap junctions with astrocytes that promote the growth of brain metastases, and that inhibition of Protocadherin 7 and/or Connexin 43 expression in cancer cells reduce progression of brain metastases. It is further based on the discovery that treatment with gap junction inhibitors tonabersat and meclofenamate inhibited progression of brain metastatic lesions and enhanced the anti-cancer activity of the conventional chemotherapeutic agent, carboplatin.
-
公开(公告)号：US20180334508A1
公开(公告)日：2018-11-22
申请号：US15984087
申请日：2018-05-18
发明人： Adrienne Boire , Joan Massague
IPC分类号： C07K16/30 , A61P35/04 , G01N33/574 , A61K31/166 , A61K31/4745 , A61K31/7068
CPC分类号： C07K16/30 , A61K31/166 , A61K31/4745 , A61K31/7068 , A61K31/7105 , A61K45/00 , A61K45/06 , A61P35/04 , G01N33/57407 , G01N33/57484
摘要： The present invention relates to methods and compositions for modulating the blood CSF barrier and for diagnosing, preventing and/or treating leptomeningeal metastasis. In particular embodiments of the invention, the permeability of the blood CSF barrier is modulated by agonists or antagonists of Complement Component 3 (C3) or its receptor.
-
公开(公告)号：US20170258758A1
公开(公告)日：2017-09-14
申请号：US15462253
申请日：2017-03-17
发明人： Joan Massague , Adrienne Boire , Qing Chen
IPC分类号： A61K31/352 , A61K31/282 , G01N33/50 , A61K31/196
CPC分类号： A61K31/352 , A61K31/196 , A61K31/282 , A61K31/555 , A61K31/7105 , A61K45/06 , A61P35/00 , A61P35/04 , G01N33/5011 , G01N2333/705 , A61K2300/00
摘要： The present invention relates to methods for treating brain metastasis by inhibiting gap junction functionality. It is based, at least in part, on the discovery that cancer cells expressing Protocadherin 7 and Connexin 43 form gap junctions with astrocytes that promote the growth of brain metastases, and that inhibition of Protocadherin 7 and/or Connexin 43 expression in cancer cells reduce progression of brain metastases. It is further based on the discovery that treatment with gap junction inhibitors tonabersat and meclofenamate inhibited progression of brain metastatic lesions and enhanced the anti-cancer activity of the conventional chemotherapeutic agent, carboplatin.
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.021 秒)
